Table 2.
Study characteristics of articles reporting on the microbiome of oesophageal adenocarcinoma compared to a non-cancer group.
| Author | Year | Country | Specimen Type | Microbiome Assessment Method |
NAT | PPI | Abx | Ref. |
|---|---|---|---|---|---|---|---|---|
| Yamamura | 2016 | Japan | Tissue | qPCR | No | - | No | [51] |
| Elliott | 2017 | UK | Tissue | 16S V1-2 + MiSeq | Mixed | - | - | [52] |
| Peters | 2017 | USA | Mouthwash | 16S V4 + MiSeq | - | - | - | [53] |
| Kageyama | 2019 | Japan | Saliva | 16S V1-2 + Ion PGM Hi-Q Seq | No | - | No | [38] |
| Yuda | 2020 | Japan | Saliva | Culture | Mixed | - | No | [12] |
| Peter | 2020 | USA | Tissue | 16S V4 + Miseq | - | Mixed | No | [57] |
| Li | 2020 | China | Tissue | 16S V3-4 + Miseq | No | - | No | [58] |
| Zhou | 2020 | Australia | Tissue | 16S V1-3 + Miseq | No | - | No | [60] |
| Lopetsu | 2020 | Italy | Tissue | 16S V3-4 + Miseq | No | N | No | [61] |
| Kawasaki | 2020 | Japan | Subgingival plaque | RT-PCR | No | - | No | [62] |
| Ishaq | 2021 | China | Faeces | 16S V3-4 + Hiseq, qPCR | - | - | No | [88] |
| Wang | 2021 | - | Tissue | TCMA database | - | - | - | [89] |
| Deng | 2021 | China | Faeces | 16S V4 + Miseq | No | No | No | [90] |
| Hao | 2022 | USA | Tissue, oral mucosal | - | - | - | No | [91] |
16S, 16S rRNA. NAT, neoadjuvant therapy. PPI, proton pump inhibitor therapy. Abx, antibiotic therapy. Y, yes. N, no.